Euromonitor International
- Item successfully added to cart!
  
  Your cart is empty
  
  Check Out View Cart

Country Report

Medicated Skin Care in

Dermatologicals in the Netherlands

20 pages, Feb 2019

US$990

Add to cart Pay by invoice

New Report Guarantee

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!

Executive Summary

New Report Guarantee

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!

PROSPECTS

Weak growth prospects for dermatologicals

Dermatologicals recorded only moderate growth in 2018, performing below average compared with OTC products overall. In contrast to other OTC categories, the further improvement in the macroeconomic environment, including rising disposable incomes, did not provide a noticeable stimulus to dermatologicals.

The continued preference for prescription products

An important long-term obstacle to stronger growth in dermatologicals is the continued preference for prescription products amongst many Dutch consumers. When patients present with potentially serious skin conditions, Dutch doctors, including dermatologists, frequently prescribe Rx dermatologicals rather than OTC alternatives, as prescription products are generally considered more effective, whilst only some OTC products are reimbursable.

Vaginal antifungals is one of few growth areas

Another challenge to the growth prospects of dermatologicals in the Netherlands is its relative maturity. As a result, demand for most types of such products appears saturated, and there are few growth opportunities left.

COMPETITIVE LANDSCAPE

Remark Pharma maintains its lead

Local manufacturer Remark Pharma remained the leader in dermatologicals in 2018, in large part thanks to the continued strong performance of its Resnan and Dr Swaab brands. The company offers a mixture of its own brands and brands from other manufacturers that are distributed under license.

Canesten Gyno performs strongly

Bayer Consumer Care and GSK Consumer Healthcare followed closely in second and third positions respectively in dermatologicals in 2018. Bayer Consumer Care owes its position predominately to the continued strength of its brands Canesten in antifungals and Bepanthen in nappy (diaper) rash treatments.

Private label is expected to remain marginal

In contrast to other OTC categories, private label is expected to remain relatively marginal in dermatologicals over the forecast period. One reason is the higher brand equity in dermatologicals, due to the perceived importance of having healthy and attractive-looking skin.

Files are delivered directly into your account within a few minutes of purchase.

Samples

Medicated Skin Care Market Sample Report Medicated Skin Care Market Sample Data

Overview

Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Medicated Skin Care industry in Netherlands with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Medicated Skin Care industry in Netherlands, our research will save you time and money while empowering you to make informed, profitable decisions.

The Medicated Skin Care in Netherlands market research report includes:

Analysis of key supply-side and demand trends
Detailed segmentation of international and local products
Historic volumes and values, company and brand market shares
Five year forecasts of market trends and market growth
Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

What is the market size of Medicated Skin Care in Netherlands?
What are the major brands in Netherlands?
What are the most popular formats for acne treatments?

Why buy this report?

Gain competitive intelligence about market leaders
Track key industry trends, opportunities and threats
Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Want to find out more about this report?

Request more information

Dermatologicals in the Netherlands - Category analysis

HEADLINES

PROSPECTS

Weak growth prospects for dermatologicals

The continued preference for prescription products

Vaginal antifungals is one of few growth areas

COMPETITIVE LANDSCAPE

Remark Pharma maintains its lead

Canesten Gyno performs strongly

Private label is expected to remain marginal

CATEGORY DATA

Table 1 Sales of Dermatologicals by Category: Value 2013-2018
Table 2 Sales of Dermatologicals by Category: % Value Growth 2013-2018
Table 3 NBO Company Shares of Dermatologicals: % Value 2014-2018
Table 4 LBN Brand Shares of Dermatologicals: % Value 2015-2018
Table 5 LBN Brand Shares of Hair Loss Treatments: % Value 2015-2018
Table 6 Forecast Sales of Dermatologicals by Category: Value 2018-2023
Table 7 Forecast Sales of Dermatologicals by Category: % Value Growth 2018-2023

Consumer Health in the Netherlands - Industry Overview

EXECUTIVE SUMMARY

Moderate value growth, largely driven by non-OTC categories

OTC sales are not (yet) lifted by the brighter macroeconomy

Pharmaceutical multinationals dominate, with private label the main rival

Supermarkets gains ground, to the detriment of chemists/pharmacies

Modest value growth over the forecast period

APPENDIX

OTC registration and classification

Vitamins and dietary supplements registration and classification

Self-medication/self-care and preventive medicine

Switches

Summary 1 OTC: Switches

MARKET INDICATORS

Table 8 Consumer Expenditure on Health Goods and Medical Services: Value 2013-2018
Table 9 Life Expectancy at Birth 2013-2018

MARKET DATA

Table 10 Sales of Consumer Health by Category: Value 2013-2018
Table 11 Sales of Consumer Health by Category: % Value Growth 2013-2018
Table 12 NBO Company Shares of Consumer Health: % Value 2014-2018
Table 13 LBN Brand Shares of Consumer Health: % Value 2015-2018
Table 14 Penetration of Private Label in Consumer Health by Category: % Value 2013-2018
Table 15 Distribution of Consumer Health by Format: % Value 2013-2018
Table 16 Distribution of Consumer Health by Format and Category: % Value 2018
Table 17 Forecast Sales of Consumer Health by Category: Value 2018-2023
Table 18 Forecast Sales of Consumer Health by Category: % Value Growth 2018-2023

Megatrends

Country Report

Dermatologicals in the Netherlands

New Report Guarantee

Executive Summary

New Report Guarantee

PROSPECTS

Weak growth prospects for dermatologicals

The continued preference for prescription products

Vaginal antifungals is one of few growth areas

COMPETITIVE LANDSCAPE

Remark Pharma maintains its lead

Canesten Gyno performs strongly

Private label is expected to remain marginal

Samples

Overview

Why buy this report?

Samples (FAQs about samples):

Want to find out more about this report?

Table of Contents

Dermatologicals in the Netherlands - Category analysis

HEADLINES

PROSPECTS

Weak growth prospects for dermatologicals

The continued preference for prescription products

Vaginal antifungals is one of few growth areas

COMPETITIVE LANDSCAPE

Remark Pharma maintains its lead

Canesten Gyno performs strongly

Private label is expected to remain marginal

CATEGORY DATA

Consumer Health in the Netherlands - Industry Overview

EXECUTIVE SUMMARY

Moderate value growth, largely driven by non-OTC categories

OTC sales are not (yet) lifted by the brighter macroeconomy

Pharmaceutical multinationals dominate, with private label the main rival

Supermarkets gains ground, to the detriment of chemists/pharmacies

Modest value growth over the forecast period

APPENDIX

OTC registration and classification

Vitamins and dietary supplements registration and classification

Self-medication/self-care and preventive medicine

Switches

MARKET INDICATORS

MARKET DATA

SOURCES

Why buy this report?

Want to find out more about this report?

Recently Viewed

Complete Catalogue

Country Reports

Strategy Reports

Recently Viewed

Complete Catalogue

Country Reports

Strategy Reports